The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

NEW YORK – A2 Biotherapeutics has treated the first solid tumor patient with its CAR T-cell therapy A2B395 in a Phase I/II clinical trial, the firm announced Thursday. Agoura Hills, California-based ...

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

The biotech has received written agreement from the agency through the START pilot program on key aspects of its trial design for evaluating NGN-401.

NEW YORK – In a safety communication earlier this week, the US Food and Drug Administration said it is investigating the risk of fatal acute liver failure with Sarepta Therapeutics' Elevidys ...